CAP-话题@MedSci - williamhill asia

#CAP#

167篇内容 | 2534人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1898078, encodeId=5f7d18980e88e, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, objectType=article, longId=729208, objectId=e8d9e29208b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d9e29208b5, replyNumber=0, likeNumber=79, createdTime=2022-10-19, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d9e29208b5, moduleTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e8d9e29208b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898077, encodeId=e67018980e7bd, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, objectType=article, longId=729099, objectId=c01ae29099c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c01ae29099c1, replyNumber=0, likeNumber=99, createdTime=2022-10-17, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c01ae29099c1, moduleTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c01ae29099c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898068, encodeId=ebbe189806856, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, objectType=article, longId=292586, objectId=8c3b292586ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3b292586ad, replyNumber=0, likeNumber=91, createdTime=2022-09-20, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3b292586ad, moduleTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8c3b292586ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898065, encodeId=8bf41898065ac, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, objectType=article, longId=221327, objectId=bdda22132edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdda22132edc, replyNumber=0, likeNumber=87, createdTime=2022-10-24, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdda22132edc, moduleTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bdda22132edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898071, encodeId=29ac18980e1ff, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, objectType=article, longId=293200, objectId=ccdc2932002c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccdc2932002c, replyNumber=0, likeNumber=74, createdTime=2022-06-20, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccdc2932002c, moduleTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ccdc2932002c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898064, encodeId=6a531898064a8, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, objectType=article, longId=219910, objectId=405021991089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405021991089, replyNumber=0, likeNumber=84, createdTime=2022-01-17, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405021991089, moduleTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=405021991089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898080, encodeId=6ac2189808012, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=肺腺癌IV期的免疫整合治疗方式：CAP方案原理介绍与病例分享, objectType=article, longId=300447, objectId=70d230044e89, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70d230044e89, replyNumber=0, likeNumber=63, createdTime=2022-04-18, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70d230044e89, moduleTitle=肺腺癌IV期的免疫整合治疗方式：CAP方案原理介绍与病例分享, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=70d230044e89)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898069, encodeId=21b31898069e3, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=PNAS：低温大气等离子体（CAP）治疗白血病的“气体”？, objectType=article, longId=293089, objectId=0de9293089c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0de9293089c1, replyNumber=0, likeNumber=81, createdTime=2022-06-28, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0de9293089c1, moduleTitle=PNAS：低温大气等离子体（CAP）治疗白血病的“气体”？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0de9293089c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898079, encodeId=d71a18980e9cc, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=CSA&TISC 2022 | 再看CAPITAL研究，中医药为抗动脉粥样硬化增添新证据, objectType=article, longId=735588, objectId=70afe355880e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70afe355880e, replyNumber=0, likeNumber=89, createdTime=2023-03-27, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70afe355880e, moduleTitle=CSA&TISC 2022 | 再看CAPITAL研究，中医药为抗动脉粥样硬化增添新证据, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=70afe355880e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898072, encodeId=eab618980e2eb, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, objectType=article, longId=293995, objectId=58f82939954d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f82939954d, replyNumber=0, likeNumber=52, createdTime=2022-08-12, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f82939954d, moduleTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=58f82939954d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898067, encodeId=acb5189806ef8, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, objectType=article, longId=291936, objectId=19f829193697, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f829193697, replyNumber=0, likeNumber=58, createdTime=2022-01-31, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f829193697, moduleTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=19f829193697)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898075, encodeId=8a7118980e5ac, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, objectType=article, longId=728247, objectId=5740e2824790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5740e2824790, replyNumber=0, likeNumber=79, createdTime=2022-11-07, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5740e2824790, moduleTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5740e2824790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898073, encodeId=680e18980e387, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=70, createdTime=2023-03-05, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898062, encodeId=26fa18980629b, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, objectType=article, longId=216808, objectId=6a23216808c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a23216808c1, replyNumber=0, likeNumber=85, createdTime=2022-01-01, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a23216808c1, moduleTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6a23216808c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898076, encodeId=58d618980e671, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, objectType=article, longId=728268, objectId=918ae28268b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=918ae28268b7, replyNumber=0, likeNumber=67, createdTime=2022-09-09, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=918ae28268b7, moduleTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=918ae28268b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898061, encodeId=dfb11898061b0, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Eur Urol：STAR-CAP临床预后系统对预测前列腺根治术后的生化复发、转移和癌症特异性死亡率的验证 , objectType=article, longId=213376, objectId=52fa2133e6cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52fa2133e6cf, replyNumber=0, likeNumber=61, createdTime=2022-03-25, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52fa2133e6cf, moduleTitle=Eur Urol：STAR-CAP临床预后系统对预测前列腺根治术后的生化复发、转移和癌症特异性死亡率的验证 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=52fa2133e6cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898074, encodeId=019a18980e408, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=59, createdTime=2022-10-31, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898059, encodeId=2485189805955, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=0, createdTime=2021-05-29, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898070, encodeId=374d18980e00a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, objectType=article, longId=292765, objectId=7f53292e6591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f53292e6591, replyNumber=0, likeNumber=63, createdTime=2022-10-19, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f53292e6591, moduleTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7f53292e6591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898060, encodeId=c5d3189806068, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, objectType=article, longId=213266, objectId=96fd2132664f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96fd2132664f, replyNumber=0, likeNumber=75, createdTime=2021-12-11, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96fd2132664f, moduleTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=96fd2132664f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

CAP

2020-05-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌

2022-10-19

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！

2022-10-17

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP

2022-09-20

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效

2022-10-24

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测

2022-06-20

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性

2022-01-17

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

肺腺癌IV期的免疫整合治疗方式：CAP方案原理介绍与病例分享

2022-04-18

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

PNAS：低温大气等离子体（CAP）治疗白血病的“气体”？

2022-06-28

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

CSA&TISC 2022 | 再看CAPITAL研究，中医药为抗动脉粥样硬化增添新证据

2023-03-27

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著

2022-08-12

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性

2022-01-31

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌

2022-11-07

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2023-03-05

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性

2022-01-01

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量

2022-09-09

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Eur Urol：STAR-CAP临床预后系统对预测前列腺根治术后的生化复发、转移和癌症特异性死亡率的验证

2022-03-25

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-10-31

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2021-05-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著

2022-10-19

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果

2021-12-11

科室
- - 订阅+
  - 更多科室
工具
服务